What are Polivy’s most frequent side effects?
Polivy (polatuzumab vedotin) is commonly associated with side effects such as low blood counts and nerve-related symptoms. In patient labeling, the most frequently reported adverse reactions include infections, decreased blood cell counts, and peripheral neuropathy. [1]
Which “frequent” side effects show up most often?
The side effects reported most often in Polivy’s prescribing information include:
- Peripheral neuropathy (numbness, tingling, or burning pain in hands/feet) [1]
- Neutropenia (low neutrophils, increasing infection risk) [1]
- Anemia (low red blood cells) [1]
- Thrombocytopenia (low platelets) [1]
- Diarrhea and nausea [1]
- Infections [1]
What should patients watch for with these side effects?
Because Polivy can lower white blood cells and affect nerves, patients and clinicians typically pay extra attention to:
- Signs of infection (fever or other infection symptoms), especially when blood counts are low [1]
- New or worsening tingling, numbness, or weakness in the extremities, which can signal peripheral neuropathy [1]
Can side effects differ by regimen or prior treatment?
Yes. Polivy is used in combination regimens (for example, with bendamustine and rituximab, or with rituximab plus other chemotherapy depending on the situation), and the overall side-effect profile can vary with the companion drugs and patient baseline health. Frequency figures in the label reflect the specific combination(s) studied. [1]
Where can I confirm the exact “most frequent” rates?
The most reliable source for “most frequent” side effects and their rates is Polivy’s full prescribing information (the adverse reactions table). [1]
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/